Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Shin J-, Choe D, Ransegnola B, Hong H-, Onyekwere I, Cross T, et al. A multifaceted cellular damage repair and prevention pathway promotes high-level tolerance to β-lactam antibiotics. EMBO Rep. 2021;22(2):e51790.

Stephens EA, Ludwicki MB, Meksiriporn B, Li M, Ye T, Monticello C, et al. Engineering Single Pan-Specific Ubiquibodies for Targeted Degradation of All Forms of Endogenous ERK Protein Kinase. ACS Synth Biol. 2021;10(9):2396-2408.

Armstrong AJ, Li X, Tucker M, Li S, Mu XJ, Eng KW, et al. Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):786-793.

Khan KM, Kothari P, Du B, Dannenberg AJ, Falcone DJ. Correction: Matrix Metalloproteinase-Dependent Microsomal Prostaglandin E Synthase-1 Expression in Macrophages: Role of TNF-α and the EP4 Prostanoid Receptor. J Immunol. 2021;207(2):746-747.

Haas T, Callum J, Grottke O, Asmis LM, Cushing MM. Response to Wirtz et al: The impact of blood product ratio and procoagulant therapy on the development of thromboembolic events in severely injured hemorrhaging trauma patients. Transfusion. 2021;61(3):991-992.

Lopez A, Patel S, Geyer JT, Racchumi J, Chadburn A, Simonson P, et al. Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. Front Oncol. 2021;11:701318.

Stern ES, Siddiqui MT. Nuclear hypochromasia: Shedding light on the "lightness" of high-grade urothelial carcinoma. Diagn Cytopathol. 2021;49(9):1032-1035.

Khan U, Ho K, Hwang EK, Peña C, Brouwer J, Hoffman K, et al. Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment. Am J Clin Oncol. 2021;44(6):247-253.

Wang X, Gkrouzman E, Andrade DC, Andreoli L, Barbhaiya M, H Belmont M, et al. COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). Lupus. 2021;30(14):2276-2285.

Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, et al. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. Nat Cancer. 2021;2(5):503-514.